First Drug to Target Cause of Cystic Fibrosis Approved
Title: First Drug to Target Cause of Cystic Fibrosis ApprovedCategory: Health NewsCreated: 2/1/2012 11:01:00 AMLast Editorial Review: 2/1/2012 (Source: MedicineNet Lungs General)
Sté Tunisienne des Maladies Respiratoires et d'Allergologie
Cercle des Bureaux - Appartement B 5-3 . 1082 Centre urbain Nord Tunis
Blog With Right Sidebar
Some Allergic Inflammation May Be Due To Exposure To Common Environmental Bacteria
Could some cases of asthma actually be caused by an allergic reaction to a common environmental bacteria? New research findings published in the Journal of Leukocyte Biology suggests that this idea may not be as far-fetched as it seems. In a research report appearing in the February 2012 print issue, researchers show a link between common environmental bacteria and airway inflammation... (Source: Health News from Medical News Today)
Against Lung Cancer Cells: To Be, or Not to Be, That Is the Problem
Tobacco smoke and radioactive radon gas impose a high risk for lung cancer. The radon-derived ionizing radiation and some components of cigarette smoke induce oxidative stress by generating reactive oxygen species (ROS).
Respiratory lung cells are subject to the ROS that causes DNA breaks, which subsequently bring about DNA mutagenesis and are intimately linked with carcinogenesis. The damaged cells by oxidative stress are often destroyed through the active apoptotic pathway. However, the ROS also perform critical signaling functions in stress responses, cell survival, and cell proliferation.
Some molecules enhance radiation-induced tumor cell killing via the reduction in DNA repair levels. Hence the DNA repair levels may be a novel therapeutic modality in overcoming drug resistance in lun...
Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease
Conclusions: A robust systemic inflammatory profile was associated with COPD. This profile was generally independent of disease severity. Because anti-tumor necrosis factor-alpha did not influence systemic inflammation, how to control the underlying pathology beyond symptom suppression remains unclear.Trial Registration: ClinicalTrials.gov, No.: NCT00056264.
Is low dose inhaled corticosteroid therapy as effective for inflammation and remodeling in asthma? A randomized, parallel group study.
Conclusions: 200mcg/day of FP was as effective as 1000mcg/day in improving symptom control, airway inflammation, lung function and AHR in adults with mild to moderate asthma in the short term. Future studies should examine potential differential effects between low and high dose combination therapy (ICS/long acting beta agonist) on inflammation and airway remodeling over longer treatment periods.